166 related articles for article (PubMed ID: 38515178)
21. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
23. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
24. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
25. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Massihnia D; Avan A; Funel N; Maftouh M; van Krieken A; Granchi C; Raktoe R; Boggi U; Aicher B; Minutolo F; Russo A; Leon LG; Peters GJ; Giovannetti E
J Hematol Oncol; 2017 Jan; 10(1):9. PubMed ID: 28061880
[TBL] [Abstract][Full Text] [Related]
26. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
27. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Alhothali M; Mathew M; Iyer G; Lawrence HR; Yang S; Chellappan S; Padmanabhan J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100813
[TBL] [Abstract][Full Text] [Related]
28. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.
Wu YH; Hung YP; Chiu NC; Lee RC; Li CP; Chao Y; Shyr YM; Wang SE; Chen SC; Lin SH; Chen YH; Kang YM; Hsu SM; Yen SH; Wu JY; Lee KD; Tseng HE; Tsai JR; Tang JH; Chiou JF; Burnouf T; Chen YJ; Wang PY; Lu LS
Eur J Cancer; 2022 May; 166():208-218. PubMed ID: 35306319
[TBL] [Abstract][Full Text] [Related]
29. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
Sandhya S; Hogenson TL; Fernandez-Zapico ME
EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
[TBL] [Abstract][Full Text] [Related]
30. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
31. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM; Feng H; Parmar K; Wang J; Kapner KS; Kochupurakkal B; Martignetti DB; Sadatrezaei G; Abrams TA; Biller LH; Giannakis M; Ng K; Patel AK; Perez KJ; Singh H; Rubinson DA; Schlechter BL; Andrews E; Hannigan AM; Dunwell S; Getchell Z; Raghavan S; Wolpin BM; Fortier C; D'Andrea AD; Aguirre AJ; Shapiro GI; Cleary JM
Clin Cancer Res; 2023 Dec; 29(24):5047-5056. PubMed ID: 37819936
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.
Chen X; Bui KC; Barat S; Thi Nguyen ML; Bozko P; Sipos B; Kalesse M; Malek NP; Plentz RR
Cancer Lett; 2017 Jul; 399():20-28. PubMed ID: 28408354
[TBL] [Abstract][Full Text] [Related]
33. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells.
Choi JI; Jang SI; Hong J; Kim CH; Kwon SS; Park JS; Lim JB
Cancer Lett; 2021 Feb; 498():42-53. PubMed ID: 33188841
[TBL] [Abstract][Full Text] [Related]
34. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
36. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
37. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
38. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
[TBL] [Abstract][Full Text] [Related]
39. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
Zhang H; Rose BJ; Pyuen AA; Thamm DH
BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
[TBL] [Abstract][Full Text] [Related]
40. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
